MiNDERA Corp. is developing an alternative to punch biopsies for diagnosing skin cancer: its microneedle device extracts biomarkers from the skin in a procedure that the start-up says is highly accurate and cost-effective for office-based diagnostic applications in dermatology.

MiNDERA Corp. is developing an alternative to punch biopsies for diagnosing skin cancer: its microneedle device extracts biomarkers from the skin in a procedure that the start-up says is highly accurate and cost-effective for office-based diagnostic applications in dermatology.

Chinese pharmaceutical giant Sinopharm’s subsidiary has finalized a licensing agreement with Israeli firm Oramed for China rights to an oral insulin capsule, paving the way for further changes in the country’s huge diabetes market. Hefei meanwhile is pushing ahead with plans to become China’s high-end insulin production base, helped by several cross-border collaborations.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2014.